NCT05788965 is a Phase 2, PHASE3 clinical trial of Semaglutide in Cystic Fibrosis, sponsored by University of Minnesota.

Who is sponsoring NCT05788965?

NCT05788965 is sponsored by University of Minnesota.

What drugs are being tested in NCT05788965?

Interventions in NCT05788965: Semaglutide.

What condition does NCT05788965 study?

NCT05788965 studies Cystic Fibrosis, Cystic Fibrosis-related Diabetes.

Is NCT05788965 still recruiting?

NCT05788965 is currently completed. Last updated 21 January 2026.

Are results published for NCT05788965?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-01-21 · How we verify

NCT05788965

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Semaglutide in CFRD

Completed Phase 2, PHASE3 Results posted Last updated 21 January 2026

What this trial tests

Phase 2, PHASE3 trial testing Semaglutide in Cystic Fibrosis in 8 participants. Completed in 31 December 2024.

Timeline

16 October 2023

Primary endpoint
23 December 2024

31 December 2024

Quick facts

Lead sponsor	University of Minnesota
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	16 October 2023
Primary completion	23 December 2024
Estimated completion	31 December 2024
Sites	1 location across United States

Drugs / interventions tested

Semaglutide (semaglutide) — full drug profile →

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →
Cystic Fibrosis-related Diabetes — all drugs for Cystic Fibrosis-related Diabetes →

Sponsor

University of Minnesota

Who can join

18 and older, any sex, with Cystic Fibrosis or Cystic Fibrosis-related Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.
Salvador R, Moutinho CG, Sousa C, Vinha AF, et al · · 2025 · cited 9× · PMID 40143174 · DOI 10.3390/ph18030399
The evolving understanding of cystic fibrosis-related diabetes in the highly effective modulator therapy era: a scoping review.
Sharpe H, Lam GY. · · 2026 · PMID 41588096 · DOI 10.1007/s00125-025-06653-7

Verify or expand the search:

Other trials of Semaglutide

Trials testing the same drug.

NCT07430332 — GLP-1 RA for Stage 1 Type 1 Diabetes · Phase 2 · not yet recruiting
NCT06977438 — Promoting Healthy Children and Youth · Phase 4 · not yet recruiting
NCT07218354 — Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial · Phase 3 · not yet recruiting
NCT07511543 — Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy · Phase 2 · not yet recruiting
NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Other University of Minnesota trials

Trials by the same sponsor.

NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05788965 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
Last refreshed: 21 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05788965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing